Condition: Plaque Psoriasis · Sponsor: Almirall, S.A.
The main aim of this study is to assess the effects of switching from another biologic to tildrakizumab on patient-reported outcomes and to assess psoriasis intensity, patient's quality of life prior and after switching and the individual rationales for switching biologics.
This description comes directly from the study's public registry record.
Senior Director Regional Medical Affairs · +43 0 15953960 · medicalat@almirall.com
Always discuss trial participation with your own doctor first.
| Gesundheitszentrum Citypark Graz | Graz, Styria, Austria | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06030076